跳到正文
原文
Medical Xpress·· 2026-10-09AI 评分55

英格兰4.5万例转移性前列腺癌分析:三年内死亡比例由56%降至47%

More men living longer with incurable prostate cancer, report finds

AI 导读

伦敦卫生与热带医学院等机构分析英格兰2015至2022年新诊断的45,339例转移性前列腺癌患者,三年内死亡比例从2015年的56%降至2022年的47%。相关研究发表于 BJU International,同期前列腺癌死亡风险下降约24%。作者表示,化疗与新型激素疗法的联合治疗正逐步进入NHS日常诊疗,但仍有近半数患者未能活过三年。

正文
man alone
Credit: Min An from Pexels

Men in England diagnosed with incurable advanced prostate cancer are more likely to survive for at least three years than they were a decade ago, according to an analysis by the London School of Hygiene & Tropical Medicine (LSHTM) and partners.

The team studied data for 45,339 men who were newly diagnosed with metastatic prostate cancer, which is currently incurable, in England between 2015 and 2022, following each man for three years after diagnosis.

Although cases are rising overall, they found the proportion who died within three years fell from 56% in 2015 to 47% in 2022.

The prostate is a gland in the male reproductive system. Prostate cancer often grows slowly with no symptoms in the early stages. However, if it spreads to other parts of the body, such as the bones, it cannot be cured and may cause serious complications.

More men are living longer in part thanks to new treatments for this type of cancer being made available through the NHS.

The findings are published in the latest annual State of the Nation report from the National Prostate Cancer Audit, produced by the National Cancer Audit Collaborating Centre (NATCAN), based at the Clinical Effectiveness Unit, an academic partnership between LSHTM and the Royal College of Surgeons of England.

The report, which includes LSHTM staff among the authors, shows the number of men diagnosed with prostate cancer in England went up by 7% in a single year, to 60,800 in 2025, while the number of men diagnosed with metastatic disease, which has spread beyond the prostate, increased to more than 6,300.

LSHTM experts led further analysis of the audit data, published in BJU International.

In this study, researchers found the risk of death from prostate cancer dropped by almost a quarter (24%) in the seven years from 2015 to 2022, amounting to thousands more men living longer now compared with 10 years ago.

First author Arjun Nathan, a doctoral student at LSHTM, urology resident surgeon, NIHR doctoral research fellow and member of the National Prostate Cancer Audit team, said, "This is genuinely encouraging news for men diagnosed with incurable prostate cancer. Looking at more than 45,000 men across England, we found survival has steadily improved: more than half of men now survive at least three years after diagnosis, up from 44% in 2015, and the risk of dying from prostate cancer fell by almost a quarter.

"Clinical trials have shown that adding newer treatments including chemotherapy and novel hormone therapy, which is known as combination therapy, helps men live longer. Our new findings show these benefits are now reaching men in everyday NHS care, not just in clinical trials. Improvements in how care is organized across the NHS, including earlier diagnosis, better scans to identify how advanced the cancer is and faster access to specialist teams, may also have played a part.

"But almost half of men still do not survive beyond three years, and not everyone who could benefit is receiving these treatments yet. Anyone diagnosed with incurable prostate cancer should talk to their care team about whether combination treatment is right for them."

Co-senior author Jan van der Meulen, professor of clinical epidemiology at LSHTM and chair of the National Prostate Cancer Audit team, said, "More and more patients are now being diagnosed with prostate cancer at an early stage.

"However, the number of patients diagnosed with prostate cancer that has already spread to the rest of the body is not coming down. For that reason, the results showing improvements in outcomes for these patients are so important.

"There are still a lot of improvements to make, both in the development of new treatments for metastatic prostate cancer and in the prompt adoption of these treatments in clinical practice."

The team examined trends in three-year mortality for men with newly diagnosed metastatic hormone-sensitive prostate cancer in England between 2015 and 2022. They studied diagnosis data from the National Cancer Registration Dataset, with death status, date of death and cause of death provided by the Civil Registration of Deaths dataset. Follow-up data were available until July 1, 2025, so men diagnosed between Jan. 1, 2015, and June 30, 2022, were included in this study.

They did not include patient-level treatment data, as the aim of the study was to capture the net effect of improvements in care at a population level. This covered the availability and use of new therapies, as well as other system-level circumstances that determine whether patients access them, such as improvements in identifying the cancer's stage, timely referral and appropriate treatment initiation.

More information

Arjun Nathan et al, Improved survival in newly diagnosed metastatic prostate cancer: a National Prostate Cancer Audit study, BJU International (2026). DOI: 10.1111/bju.70432

Who's behind this story?

Gaby Clark

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Andrew Zinin

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: More men living longer with incurable prostate cancer, report finds (2026, October 8) retrieved 8 October 2026 from https://medicalxpress.com/news/2026-10-men-longer-incurable-prostate-cancer.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com